Search

Your search keyword '"Strazzabosco, M."' showing total 571 results

Search Constraints

Start Over You searched for: Author "Strazzabosco, M." Remove constraint Author: "Strazzabosco, M." Search Limiters Available in Library Collection Remove constraint Search Limiters: Available in Library Collection
571 results on '"Strazzabosco, M."'

Search Results

1. Adherence to Tumor Board Recommendations in the Treatment of Patients with Hepatocellular Carcinoma

2. European Society for Organ Transplantation (ESOT) Consensus Statement on Outcome Measures in Liver Transplantation According to Value-Based Health Care

3. Inflammatory pathways and cholangiocarcinoma risk mechanisms and prevention

4. The Neglected Role of Bile Duct Epithelial Cells in NASH

5. Tumor microenvironment and immunology of cholangiocarcinoma

6. Translational Value of Tumor-Associated Lymphangiogenesis in Cholangiocarcinoma

7. Corrigendum to ‘An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs’ [J Hepatol 2021;75(3):572–581] (Journal of Hepatology (2021) 75(3) (572–581), (S0168827821003342), (10.1016/j.jhep.2021.04.055))

8. Intrahepatic cholangiocarcinoma developing in patients with metabolic syndrome is characterized by Osteopontin overexpression in the tumor stroma

11. Short-term effectiveness of dapagliflozin versus DPP-4 inhibitors in elderly patients with type 2 diabetes: a multicentre retrospective study

15. Corrigendum to ‘An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs’ [J Hepatol 2021;75(3):572–581] (Journal of Hepatology (2021) 75(3) (572–581), (S0168827821003342), (10.1016/j.jhep.2021.04.055))

16. Congenital cystic lesions of the biliary tree

17. Cholangiocarcinoma

18. Fibrocystic liver disease: Novel concepts and translational perspectives

19. X Chromosome Contribution to the Genetic Architecture of Primary Biliary Cholangitis

20. An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs

21. Pathological characteristics of liver sinusoidal thrombosis in COVID-19 patients: A series of 43 cases

22. Liver injury in COVID-19 and IL-6 trans-signaling-induced endotheliopathy

23. Clinical outcome indicators in chronic hepatitis B and C: A primer for value-based medicine in hepatology

24. Cholangiocyte biology and pathobiology

25. Liver Matrix in Benign and Malignant Biliary Tract Disease

26. The Emerging Role of Macrophages in Chronic Cholangiopathies Featuring Biliary Fibrosis: An Attractive Therapeutic Target for Orphan Diseases

27. Cholangiocarcinoma 2020: the next horizon in mechanisms and management

28. Introduction to the Physiology, Immunology and Pathology of the Liver and Biliary Tree

29. Pathophysiology of Cystic Fibrosis Liver Disease: A Channelopathy Leading to Alterations in Innate Immunity and in Microbiota

30. Animal models of cholestasis: An update on inflammatory cholangiopathies

31. The challenges of primary biliary cholangitis: What is new and what needs to be done

32. Fibrocystic liver disease

33. Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data

34. Liver diseases in the dish: iPSC and organoids as a new approach to modeling liver diseases

35. Cholangiocyte pathobiology

36. Modeling of implementation of the new Organ Procurement and Transplantation Network/United Network for Organ Sharing policy for patients with hepatocellular carcinoma

37. The tumour microenvironment and immune milieu of cholangiocarcinoma

38. Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data

39. Targeted therapies for extrahepatic cholangiocarcinoma: preclinical and clinical development and prospects for the clinic

40. X Chromosome Contribution to the Genetic Architecture of Primary Biliary Cholangitis

41. Forecasting Hepatitis C liver disease burden on real-life data. Does the hidden iceberg matter to reach the elimination goals?

42. Association of kidney disease measures with risk of renal function worsening in patients with type 1 diabetes 11 Medical and Health Sciences 1103 Clinical Sciences

43. Forecasting Hepatitis C liver disease burden on real-life data. Does the hidden iceberg matter to reach the elimination goals?

44. Animal models of cholangiocarcinoma: What they teach us about the human disease

45. The optimal timing of hepatitis C therapy in liver transplant-eligible patients: Cost-effectiveness analysis of new opportunities

46. Corrigendum to “Premature ovarian senescence and a high miscarriage rate impair fertility in women with HCV” [J Hepatol 68 (2018) 33–41](S0168827817322596)(10.1016/j.jhep.2017.08.019)

47. Impatto dei farmaci anti virali ad azione diretta sulla cura dei pazienti con epatite C: un approccio di value-based medicine

48. Continuous Subcutaneous Insulin Infusion in Italy: Third National Survey

49. Cholangiocarcinoma 2020: the next horizon in mechanisms and management

50. Health related quality of life in chronic liver diseases

Catalog

Books, media, physical & digital resources